5/28
07:38 am
cvac
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK [Yahoo! Finance]
Medium
Report
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK [Yahoo! Finance]
5/28
07:20 am
cvac
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Low
Report
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
5/23
07:20 am
cvac
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Low
Report
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
5/22
04:26 pm
cvac
Human Bird Flu Cases Spur Retail Trader Rush Into Vaccine Stocks [Yahoo! Finance]
Low
Report
Human Bird Flu Cases Spur Retail Trader Rush Into Vaccine Stocks [Yahoo! Finance]
4/26
07:23 am
cvac
CureVac (NASDAQ: CVAC) was downgraded by analysts at Leerink Partnrs from an "outperform" rating to a "market perform" rating.
Neutral
Report
CureVac (NASDAQ: CVAC) was downgraded by analysts at Leerink Partnrs from an "outperform" rating to a "market perform" rating.
4/25
08:25 am
cvac
CureVac (NASDAQ: CVAC) was downgraded by analysts at SVB Leerink LLC from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $12.00.
Medium
Report
CureVac (NASDAQ: CVAC) was downgraded by analysts at SVB Leerink LLC from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $12.00.
4/24
07:40 am
cvac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update [Yahoo! Finance]
Low
Report
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update [Yahoo! Finance]
4/24
07:33 am
cvac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer [Yahoo! Finance]
Low
Report
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer [Yahoo! Finance]
4/24
07:33 am
cvac
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK [Yahoo! Finance]
Low
Report
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK [Yahoo! Finance]
4/24
07:30 am
cvac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Low
Report
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
4/24
07:20 am
cvac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Low
Report
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4/24
07:20 am
cvac
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Low
Report
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4/23
11:31 am
cvac
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30% [Yahoo! Finance]
Low
Report
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30% [Yahoo! Finance]
4/18
07:15 am
cvac
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
High
Report
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
4/16
07:33 am
cvac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines [Yahoo! Finance]
Low
Report
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines [Yahoo! Finance]
4/16
07:15 am
cvac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Low
Report
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4/5
10:25 am
cvac
CureVac (NASDAQ: CVAC) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Low
Report
CureVac (NASDAQ: CVAC) had its "neutral" rating re-affirmed by analysts at Guggenheim.
4/4
07:28 am
cvac
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK [Yahoo! Finance]
Low
Report
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK [Yahoo! Finance]
4/4
07:15 am
cvac
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Low
Report
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK